TScan Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 8, 2023 and accepted by EDGAR at Mar 8, 2023, 07:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $13.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $59.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$66.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $1.2m | us-gaap:InterestExpense |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$66.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$2.75 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$2.75 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 24,048,267 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$66.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $4.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $120.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $124.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $199.1m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $17.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $99.7m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $29.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-12-31 | $99.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-006589. Last ingested by Listed: Oct 26, 2026, 08:08 ET. Listed shows no prices and gives no investment advice.